DHP Korea Co. Ltd (131030) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of DHP Korea Co. Ltd stock KRW 6,684, price KRW 5,880, upside +13.7%, quality 52 out of 100. Rating: undervalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range 4,585 KRW – 19,260 KRW · fair‑value band 6,684 KRW – 7,037 KRW · the 5,880 KRW price screens below the 6,684 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow DHP Korea Co. in your weekly email
Every Wednesday you see whether DHP Korea Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
OPTUS Pharmaceutical Co., Ltd. provides ophthalmic solutions in South Korea. The company offers dry eye preparation, antibiotics, anti-allergic preparation, steroids preparation, glaucoma treatment, and retinopathy treatment products.
Show moreShow less
It also provides ETC, OTC, cosmetics, healthcare, and other products, as well as single-dose unit eye drops and eye care products under OEU& brand name.
The company was formerly known as DHP Korea Co., Ltd. OPTUS Pharmaceutical Co., Ltd. was founded in 2002 and is headquartered in Cheongju, South Korea.
Stock analysis
DHP Korea Co. Ltd (131030) currently trades at 5,880 KRW, while our model-based Fair Value estimate is 6,684 KRW, implying the stock looks roughly 12% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 13,221 KRW per share, and 9 of the 16 models we run sit above the 5,880 KRW price.
Bear case: the Dividend Discount group reads lowest at 936.55 KRW, and 7 of the 16 models stay below the price. Data coverage for this calculation is high.
Scenario range: 6,684 KRW (bear) to 7,037 KRW (bull), the price of 5,880 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
DHP Korea Co. Ltd reported revenue of 87.2B KRW in FY2025 versus 57.3B KRW in FY2021, a compound +11.0%/yr. Reported net income was 11.4B KRW in FY2025, compounding +3.5%/yr from FY2021.
Key figures
Market cap 101B KRW (≈ $74.9M) Micro · P/E ratio 7.4 · P/S ratio 1.07 · EPS (TTM) 791.51 KRW · Dividend yield 1.5% · Net margin 14.6% · Return on equity 8.4% · Return on assets (EBIT) 5.3% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 45 out of 100 (low confidence).
What moves the price
The share trades about 69% below its 52-week high and 20% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 14%, 131030 screens cheaper than that median.
Fair Value models
Bear6,684 KRWFair Value 6,684 KRWBull7,037 KRW
Price 5,880 KRW · Upside +13.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (678.75 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.42/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+6.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.5%
Start year 2020 (pandemic). Over 10 years: +8.5% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−2.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−3.6%
Dividend (yield on the price)1.5%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−3.6% vs 0.5%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.26% → 10%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 9/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score52 · Below median
Fair Value upside+13.7% · Above median
Profitability
Return on equity (12 months)8.4% · Above median
Return on assets5.9% · Above median
Net margin (12 months)14.6% · Above median
Operating margin (12 months)9.4% · Below median
Growth and dividend
Revenue growth (quarter YoY)13.1% · Above median
Dividend yield (12 months)1.5% · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "DHP Korea Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/131030
Frequently asked questions
Is DHP Korea Co. Ltd (131030) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 6,684 KRW versus a price of 5,880 KRW, about +14% upside (undervalued).
What is the fair value of 131030?
Our model-based fair value for DHP Korea Co. Ltd is 6,684 KRW (as of Nov 9, 2026), built from audited fundamentals. The current price: 5,880 KRW.
What is the quality score of 131030?
DHP Korea Co. Ltd has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for DHP Korea Co. Ltd (131030)?
Our model-based price target is the fair value of 6,684 KRW (as of Nov 9, 2026) from 16 valuation models. Cautious scenario 6,684 KRW, optimistic scenario 7,037 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the DHP Korea Co. Ltd stock forecast for 2026?
Our models put fair value at 6,684 KRW, about +14% upside versus a price of 5,880 KRW (undervalued). Cautious scenario 6,684 KRW, optimistic scenario 7,037 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of DHP Korea Co. Ltd (131030)?
DHP Korea Co. Ltd reported trailing-twelve-month revenue of about 94.5B KRW (latest available figure, as of Nov 9, 2026).
Does DHP Korea Co. Ltd pay a dividend?
DHP Korea Co. Ltd currently shows a dividend yield of 1.49% relative to its recent price (as of Nov 9, 2026).
How much is the dividend of DHP Korea Co. Ltd (131030)?
DHP Korea Co. Ltd has a dividend yield of 1.5%.
What is the intrinsic value of DHP Korea Co. Ltd (131030)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For DHP Korea Co. Ltd it is 6,684 KRW per share (as of Nov 9, 2026), against a price of 5,880 KRW. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is DHP Korea Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 131030 trades below its calculated fair value: price 5,880 KRW, fair value 6,684 KRW, a gap of about +14% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 131030?
No. The price is what the market pays today (5,880 KRW); the fair value is what the company's own numbers justify (6,684 KRW). For DHP Korea Co. Ltd the two are 804.46 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is DHP Korea Co. Ltd worth?
The market values DHP Korea Co. Ltd at about 101B KRW (market capitalisation, as of Nov 9, 2026). Per share that is 5,880 KRW; our models calculate a fair value of 6,684 KRW per share.
What do the bullish and bearish scenarios say about 131030?
Our models span a range for DHP Korea Co. Ltd: cautious scenario 6,684 KRW, base 6,684 KRW, optimistic 7,037 KRW per share (as of Nov 9, 2026, price 5,880 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 131030?
DHP Korea Co. Ltd trades at a price-to-earnings ratio of 7.4 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 6,684 KRW is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings: 9.7. Other multiples: P/B 0.6, P/S 1.1, EV/EBITDA 5.3.
How solid is the balance sheet of DHP Korea Co. Ltd (131030)?
Balance-sheet figures for DHP Korea Co. Ltd (as of Nov 9, 2026): return on equity 8.4%. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is 131030 from its 52-week high?
DHP Korea Co. Ltd trades at 5,880 KRW, about 69% below its 52-week high of 19,260 KRW and 20% above the low of 4,900 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 6,684 KRW is for.
Which stocks are comparable to DHP Korea Co. Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is DHP Korea Co. Ltd stock attractive at the current price?
The data as of Nov 9, 2026: price 5,880 KRW, calculated fair value 6,684 KRW (+14%), Quality Score 52/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 131030 calculated?
We run DHP Korea Co. Ltd through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 6,684 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. DHP Korea Co. Ltd currently trades 12% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of DHP Korea Co. Ltd (131030)?
The closing price on Nov 6, 2026 was 5,880 KRW. Our model-based fair value is 6,684 KRW, about +14% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with DHP Korea Co. Ltd right now?
The price is below even our cautious bear case (6,684 KRW). The market is more pessimistic than our downside scenario. The models converge in a tight band (6,684 KRW to 7,037 KRW), unusually little disagreement for a valuation.
Key figures of DHP Korea Co. Ltd
How large is the market capitalisation of DHP Korea Co. Ltd (131030)?
The market capitalisation of DHP Korea Co. Ltd is 101B KRW (≈ $74.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of DHP Korea Co. Ltd (131030)?
The price-to-sales ratio of DHP Korea Co. Ltd is 1.07 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of DHP Korea Co. Ltd (131030)?
Earnings per share at DHP Korea Co. Ltd are 791.51 KRW (price ÷ EPS = P/E 7.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of DHP Korea Co. Ltd (131030)?
The dividend yield of DHP Korea Co. Ltd is 1.5% (payout 11.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of DHP Korea Co. Ltd (131030)?
The net margin of DHP Korea Co. Ltd is 14.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of DHP Korea Co. Ltd (131030)?
The return on equity (ROE) of DHP Korea Co. Ltd is 8.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of DHP Korea Co. Ltd (131030)?
On an EBIT basis the return on assets of DHP Korea Co. Ltd is 5.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of DHP Korea Co. Ltd (131030)?
The operating margin of DHP Korea Co. Ltd is 9.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at DHP Korea Co. Ltd (131030)?
Revenue at DHP Korea Co. Ltd is growing +13.1% versus a year earlier (3y avg +14.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at DHP Korea Co. Ltd (131030)?
Earnings per share at DHP Korea Co. Ltd are growing +20.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does DHP Korea Co. Ltd (131030) generate?
The free cash flow of DHP Korea Co. Ltd is −28.8B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch DHP Korea Co. Ltd in the live analysis
One click puts DHP Korea Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 9, 2026